Approximately 30% of patients with prostate cancer have experienced biochemical recurrence (BCR) within ten years after resection [13], and the critical predictors of BCR include prostate-specific antigen (PSA), the Gleason score, and the pathological stage. This evidence concerns the gene KLK3 and prostate cancer.